A scientometric analysis of immunotherapies for gliomas: Focus on GBM.

in Asian journal of surgery by Yang Xing, Feroza Yasinjan, Huayue Geng, Minghua He, Mei Yang, Yufei Gao, Jinnan Zhang, Ling Zhang, Baofeng Guo

TLDR

  • This study looks at how scientists are trying to find new ways to treat a type of brain tumor called glioblastoma. The standard treatment for this type of tumor has been the same for a long time, and it hasn't been very effective. Scientists are now trying to use immunotherapies, which are treatments that use the body's immune system to fight the tumor. The study uses a special tool called CiteSpace and VOS viewer to look at all the research that has been done on this topic. The study found that this field is becoming more popular and that there are several areas where scientists are trying to find new ways to use immunotherapies to treat glioblastoma, like TME, ICBs, CAR-T cells, vaccines, and OVs. The study hopes that this information will help scientists find new ways to treat glioblastoma and improve survival outcomes.

Abstract

Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. The standard therapy for GBM has remained unchanged for nearly two decades, with no significant improvement in survival outcomes. Despite several barriers such as the tumor microenvironment (TME) and blood-brain barrier, immunotherapies bring new hope for the treatment of GBM. To better understand the development and progress of immunotherapies in GBM, we made this scientometric analysis of this field. A total of 3753 documents were obtained from the Web of Science Core Collection, with publication years ranging from 1999 to 2022. The Web of Science platform, CiteSpace, and VOS viewer were used to conduct the scientometric analysis. The results of scientometric analysis showed that this field has recently become a popular topic of interest. The United States had the most publications among 89 countries or regions. Keyword analysis indicated significant areas in the field of immunotherapies for GBM, especially TME, immune checkpoint blockades (ICBs), chimeric antigen receptor T (CAR-T) cells, vaccines, and oncolytic viruses (OVs). Overall, we hope that this scientometric analysis can provide insights for researchers and promote the development of this field.

Overview

  • The study focuses on the development and progress of immunotherapies in glioblastoma (GBM), a prevalent primary malignant brain tumor with no significant improvement in survival outcomes despite standard therapy. The study uses a scientometric analysis to understand the field's recent popularity and significant areas in immunotherapies for GBM, including TME, ICBs, CAR-T cells, vaccines, and OVs. The study aims to provide insights for researchers and promote the development of this field.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions or interventions in the field of immunotherapies for GBM. The results of the scientometric analysis showed that the field has recently become a popular topic of interest, with the United States having the most publications among 89 countries or regions. Keyword analysis indicated significant areas in the field of immunotherapies for GBM, especially TME, ICBs, CAR-T cells, vaccines, and OVs.

Implications and Future Directions

  • The study's findings suggest that immunotherapies bring new hope for the treatment of GBM, with several barriers such as TME and blood-brain barrier. The study highlights the importance of understanding the development and progress of immunotherapies in GBM, which could lead to improved survival outcomes. Future research directions could focus on developing more effective immunotherapies, exploring new targets, and addressing the limitations of current immunotherapies.
Read Full Article